{
  "id": "kymr_corporate_2026",
  "name": "Kymera Therapeutics Corporate Presentation January 2026",
  "type": "corporate_presentation",
  "company": "KYMR",
  "date": "2026-01-13",
  "event": "JPM Healthcare Conference",
  "total_slides": 67,
  "extraction_status": "pending",
  "verification_status": "unverified",
  "slide_map": {
    "1": {"title": "Revolutionizing Immunology", "relevant_assets": []},
    "2": {"title": "Forward Looking Statements", "relevant_assets": []},
    "3": {"title": "Well Positioned to Redefine Immunology with Novel Oral Medicines", "relevant_assets": []},
    "4": {"title": "Kymera: Industry Leader in Developing Oral Degrader Medicines", "relevant_assets": []},
    "5": {"title": "Immunology Remains a Large Underserved Market", "relevant_assets": []},
    "6": {"title": "Advanced Systemic Therapies Are Mostly Injectable Biologics", "relevant_assets": []},
    "7": {"title": "Degraders Allow for Continuous, Biologics-like, Complete Pathway", "relevant_assets": []},
    "8": {"title": "Unique Target Selection Strategy Drives Best-In-Class Pipeline", "relevant_assets": ["kt621", "kt579", "kt485"]},
    "9": {"title": "Oral Degraders with Biologics-like Efficacy Can Transform Immunology", "relevant_assets": []},
    "10": {"title": "Opportunity to Address a Wide Range of Immunology Indications", "relevant_assets": ["kt621", "kt579"]},
    "11": {"title": "Building a Best-In-Industry Oral Immunology Pipeline", "relevant_assets": ["kt621", "kt579", "kt485"]},
    "12": {"title": "First-in-Class Oral STAT6 Degrader", "relevant_assets": ["kt621"]},
    "13": {"title": "KT-621 Summary", "relevant_assets": ["kt621"]},
    "14": {"title": "STAT6 Transcription Factor: Highly Validated but Undrugged Target", "relevant_assets": ["kt621"]},
    "15": {"title": "STAT6 Opportunity to Serve Millions of Patients with Type 2 Inflammation", "relevant_assets": ["kt621"]},
    "16": {"title": "Current Treatments Do Not Address Patients' Needs", "relevant_assets": ["kt621"]},
    "17": {"title": "KT-621 Development Plan Enables Efficient Path to Registration", "relevant_assets": ["kt621"]},
    "18": {"title": "KT-621 Data Provide Validation and Derisk Future Clinical Trials", "relevant_assets": ["kt621"]},
    "19": {"title": "KT-621: BROADEN2 Phase 2b Trial", "relevant_assets": ["kt621"]},
    "20": {"title": "KT-621: BREADTH Phase 2b Trial", "relevant_assets": ["kt621"]},
    "21": {"title": "KT-621 Phase 1a Healthy Volunteer Study", "relevant_assets": ["kt621"]},
    "22": {"title": "KT-621: Compelling Clinical Profile", "relevant_assets": ["kt621"]},
    "23": {"title": "BroADen KT-621 Phase 1b AD Study Surpassed Objectives", "relevant_assets": ["kt621"]},
    "24": {"title": "BroADen Study Design", "relevant_assets": ["kt621"]},
    "25": {"title": "KT-621 Achieved Deep STAT6 Degradation in Blood and Skin", "relevant_assets": ["kt621"]},
    "26": {"title": "Robust Impact on All Disease-Relevant Biomarkers of Type 2 Inflammation", "relevant_assets": ["kt621"]},
    "27": {"title": "KT-621 Significantly Downregulated Core Type 2 Inflammation Genes", "relevant_assets": ["kt621"]},
    "28": {"title": "KT-621 Achieved Rapid and Robust Reductions in EASI", "relevant_assets": ["kt621"]},
    "29": {"title": "KT-621 Achieved Robust and Consistent Reductions in Itch", "relevant_assets": ["kt621"]},
    "30": {"title": "KT-621 Achieved Robust Improvement in Patient Reported Outcomes", "relevant_assets": ["kt621"]},
    "31": {"title": "KT-621 Achieved Robust Impact on FeNO and ACQ-5 in AD Patients with Asthma", "relevant_assets": ["kt621"]},
    "32": {"title": "KT-621 Achieved Robust Impact on TNSS and RQLQ in AD Patients with AR", "relevant_assets": ["kt621"]},
    "33": {"title": "KT-621 Demonstrated Robust Improvements Across All Key Clinical Endpoints", "relevant_assets": ["kt621"]},
    "34": {"title": "KT-621 BroADen Phase 1b Safety Summary", "relevant_assets": ["kt621"]},
    "35": {"title": "Kymera Completes the Clinical Translation of STAT6 Degradation", "relevant_assets": ["kt621"]},
    "36": {"title": "First-in-Class Oral IRF5 Degrader", "relevant_assets": ["kt579"]},
    "37": {"title": "KT-579 Overview", "relevant_assets": ["kt579"]},
    "38": {"title": "IRF5: Targeting a Genetically Validated Undrugged Transcription Factor", "relevant_assets": ["kt579"]},
    "39": {"title": "Stimuli and Cell Specific IRF5 Activation in Clinically Validated Pathways", "relevant_assets": ["kt579"]},
    "40": {"title": "IRF5 Genetically Validated in Multiple Autoimmune Diseases", "relevant_assets": ["kt579"]},
    "41": {"title": "IRF5: A Novel Mechanism in High Unmet Need Indications", "relevant_assets": ["kt579"]},
    "42": {"title": "KT-579: An Exquisitely Selective and Picomolar Oral IRF5 Degrader", "relevant_assets": ["kt579"]},
    "43": {"title": "KT-579 Potently Inhibits Production of Key Pro-Inflammatory Cytokines", "relevant_assets": ["kt579"]},
    "44": {"title": "KT-579 Effectively Blocks TLR Induced Pro-inflammatory Cytokines", "relevant_assets": ["kt579"]},
    "45": {"title": "KT-579 Superior Activity in the MRL/lpr Model of Lupus", "relevant_assets": ["kt579"]},
    "46": {"title": "KT-579 Significantly Decreases IgG, Complement 3 (C3) and Renal Pathology", "relevant_assets": ["kt579"]},
    "47": {"title": "IRF5 Degradation Demonstrated Generally Better Outcomes than Approved Therapies", "relevant_assets": ["kt579"]},
    "48": {"title": "KT-579 Reduces Joint Swelling in a Mouse Model of RA", "relevant_assets": ["kt579"]},
    "49": {"title": "KT-579 Potently Degrades at Low Oral Doses in NHP", "relevant_assets": ["kt579"]},
    "50": {"title": "Partnered Oral Degrader Programs", "relevant_assets": ["kt485"]},
    "51": {"title": "IRAK4 Overview", "relevant_assets": ["kt485"]},
    "52": {"title": "CDK2 Overview", "relevant_assets": []},
    "53": {"title": "2026: Catalysts for Growth", "relevant_assets": ["kt621", "kt579", "kt485"]},
    "54": {"title": "Thank You", "relevant_assets": []},
    "55": {"title": "Appendix: First-in-Class Oral STAT6 Degrader", "relevant_assets": ["kt621"]},
    "56": {"title": "KT-621: Compelling Preclinical Profile", "relevant_assets": ["kt621"]},
    "57": {"title": "KT-621 SAD & MAD Study Results", "relevant_assets": ["kt621"]},
    "58": {"title": "KT-621 BroADen Phase 1b Demographics", "relevant_assets": ["kt621"]},
    "59": {"title": "KT-621 BroADen Phase 1b Baseline Disease Characteristics", "relevant_assets": ["kt621"]},
    "60": {"title": "Example of Clinical and Biomarker Response to KT-621 in BroADen", "relevant_assets": ["kt621"]},
    "61": {"title": "Atopic Dermatitis: Intensely Pruritic, Chronic and Underserved Disease", "relevant_assets": ["kt621"]},
    "62": {"title": "Asthma: Chronic, Inflammatory Lung Disease", "relevant_assets": ["kt621"]},
    "63": {"title": "Appendix: Partnered Programs", "relevant_assets": ["kt485"]},
    "64": {"title": "IRAK4 Biology and Target Rationale", "relevant_assets": ["kt485"]},
    "65": {"title": "CDK2 Molecular Glue Degrader Advantage", "relevant_assets": []},
    "66": {"title": "Abbreviations", "relevant_assets": []},
    "67": {"title": "Abbreviations (continued)", "relevant_assets": []}
  }
}
